Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR et al (2022) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895–e1032

PubMed  Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726

Article  PubMed  CAS  Google Scholar 

Packer M (1992) The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20(1):248–254

Article  PubMed  CAS  Google Scholar 

Biegus J, Nawrocka-Millward S, Zymlinski R, Fudim M, Testani J, Marciniak D, Rosiek-Biegus M, Ponikowska B, Guzik M, Garus M et al (2021) Distinct renin/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure. Int J Cardiol 345:54–60

Article  PubMed  Google Scholar 

Malgie J, Clephas PRD, Brunner-La Rocca HP, de Boer RA, Brugts JJ (2023) Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy. Heart Fail Rev 28(5):1221–1234

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hamada T, Kubo T, Kawai K, Nakaoka Y, Yabe T, Furuno T, Yamada E, Kitaoka H, Ys Kochi (2022) Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction. ESC Heart Fail 9(3):1853–1863

Article  PubMed  PubMed Central  Google Scholar 

Hamada T, Kubo T, Kawai K, Nakaoka Y, Yabe T, Furuno T, Yamada E, Kitaoka H, Kochi YS (2023) Frailty interferes with the guideline-directed medical therapy in heart failure patients with reduced ejection fraction. ESC Heart Fail 10(1):223–233

Article  PubMed  Google Scholar 

Abe T, Jujo K, Maeda D, Saito K, Ogasahara Y, Saito K, Saito H, Iwata K, Konishi M, Kitai T et al (2023) The interaction between physical frailty and prognostic impact of heart failure medication in elderly patients. ESC Heart Fail 10(3):1698–1705

Article  PubMed  PubMed Central  Google Scholar 

Fiuzat M, Ezekowitz J, Alemayehu W, Westerhout CM, Sbolli M, Cani D, Whellan DJ, Ahmad T, Adams K, Pina IL et al (2020) Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT trial: A secondary analysis of a randomized clinical trial. JAMA Cardiol 5(7):757–764

Article  PubMed  Google Scholar 

Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, Duffy CI, Hill CL, McCague K, Patterson JH et al (2019) Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 73(19):2365–2383

Article  PubMed  PubMed Central  Google Scholar 

Jarjour M, Henri C, de Denus S, Fortier A, Bouabdallaoui N, Nigam A, O’Meara E, Ahnadi C, White M, Garceau P et al (2020) Care gaps in adherence to heart failure guidelines: Clinical inertia or physiological limitations? JACC Heart Fail 8(9):725–738

Article  PubMed  Google Scholar 

Swat SA, Helmkamp LJ, Tietbohl C, Thompson JS, Fitzgerald M, McIlvennan CK, Harger G, Ho PM, Ahmad FS, Ahmad T et al (2023) Clinical inertia among outpatients with heart failure: Application of treatment nonintensification taxonomy to EPIC-HF trial. JACC Heart Fail 11(11):1579–1591

Article  PubMed  Google Scholar 

Novosadova M, Gianchetti L, Takagi K, Morishetty P, Gaeta L, Edwards C, Davison BA, Picod A, Mebazaa A, Cotter G (2023) Global differences in acute heart failure treatment: analysis of the STRONG-HF site feasibility questionnaire. ESC Heart Fail 10(4):2236–2247

Article  PubMed  PubMed Central  Google Scholar 

Witte KK, Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Fonseca C, Lonn E, Noè A, Schwende H, Butylin D et al (2023) Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure. ESC Heart Fail 10(1):80–89

Article  PubMed  Google Scholar 

Cotter G, Davison BA, Lam CSP, Metra M, Ponikowski P, Teerlink JR, Mebazaa A (2023) Acute heart failure is a malignant process: But we can induce remission. J Am Heart Assoc 12(21):e031745

Article  PubMed  PubMed Central  Google Scholar 

Harrington J, Fonarow GC, Khan MS, Hernandez A, Anker S, Bohm M, Greene SJ, Felker GM, Vaduganathan M, Butler J (2023) Medication-attributable adverse events in heart failure trials. JACC Heart Fail 11(4):425–436

Article  PubMed  PubMed Central  Google Scholar 

Abdin A, Komajda M, Borer JS, Ford I, Tavazzi L, Batailler C, Swedberg K, Rosano GMC, Mahfoud F, Bohm M et al (2023) Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial). ESC Heart Fail 10(5):2895–2902

Article  PubMed  PubMed Central  Google Scholar 

Tomasoni D, Davison B, Adamo M, Pagnesi M, Mebazaa A, Edwards C, Arrigo M, Barros M, Biegus J, Celutkiene J et al (2024) Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial. J Card Fail 30(4):525–537

Article  PubMed  Google Scholar 

Esteban-Fernandez A, Diez-Villanueva P, Vicent L, Bover R, Gomez-Bueno M, De Juan J, Iniesta AM, Garcia-Aguado M, Martinez-Selles M (2020) Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort. Rev Esp Geriatr Gerontol 55(2):65–69

Article  PubMed  Google Scholar 

Goyal P, Zullo AR, Gladders B, Onyebeke C, Kwak MJ, Allen LA, Levitan EB, Safford MM, Gilstrap L (2023) Real-world safety of neurohormonal antagonist initiation among older adults following a heart failure hospitalization. ESC Heart Fail 10(3):1623–1634

Article  PubMed  PubMed Central  Google Scholar 

Monteiro P, Bergenstal RM, Toural E, Inzucchi SE, Zinman B, Hantel S, Kis SG, Kaspers S, George JT, Fitchett D (2019) Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME(R) trial. Age Ageing 48(6):859–866

Article  PubMed  PubMed Central  Google Scholar 

Girerd N, Von Hunolstein JJ, Pellicori P, Bayes-Genis A, Jaarsma T, Lund LH, Bilbault P, Boivin JM, Chouihed T, Costa J et al (2022) Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction. ESC Heart Fail 9(4):2063–2069

Article  PubMed  PubMed Central  Google Scholar 

Cotter G, Davison BA, Adams KF Jr, Ambrosy AP, Atabaeva L, Beavers CJ, Bhatt AS, Givertz MM, Grodin JL, Lala A et al (2024) Effective medications can work only in patients who take them: Implications for post-acute heart failure care. Eur J Heart Fail 26(1):1–4

Article  PubMed  Google Scholar 

Chioncel O, Celutkiene J, Belohlavek J, Kamzola G, Lainscak M, Merkely B, Milicic D, Nessler J, Ristic AD, Sawielajc L et al (2024) Heart failure care in the Central and Eastern Europe and Baltic region: Status, barriers, and routes to improvement. ESC Heart Fail. https://doi.org/10.1002/ehf2.14687

Article  PubMed  Google Scholar 

Loeb M, Roy A, Dokainish H, Dans A, Palileo-Villanueva LM, Karaye K, Zhu J, Liang Y, Goma F, Damasceno A et al (2022) Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial. Lancet Glob Health 10(12):e1835–e1844

Article  PubMed  CAS  Google Scholar 

Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL et al (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361(14):1329–1338

Article  PubMed  Google Scholar 

Kocabas U, Ergin I, Kivrak T, Yilmaz Oztekin GM, Tanik VO, Ozdemir I, Avci Demir F, Dogdus M, Sen T, Altinsoy M et al (2023) Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction. ESC Heart Fail 10(6):3677–3689

Article  PubMed  PubMed Central  Google Scholar 

Biegus J, Moayedi Y, Saldarriaga C, Ponikowski P (2022) Getting ahead of the game: in-hospital initiation of HFrEF therapies. Eur Heart J Suppl 24(Suppl L):L38–L44

Article  PubMed  PubMed Central  CAS  Google Scholar 

Palin V, Drozd M, Garland E, Malik A, Straw S, McGinlay M, Simms A, Gatenby VK, Sengupta A, Levelt E et al (2022) Reduction of heart failure guideline-directed medication during hospitalization: prevalence, risk factors, and outcomes. ESC Heart Failure 9(5):3298–3307

Article  PubMed  PubMed Central